Alzheimer's Disease Drug Development Strategies

Alzheimer’s disease (AD) drug development encompasses symptomatic treatments that improve cognition or behaviour, and disease-modifying therapies aimed at the underlying biology of amyloid-β, tau and related pathways. Efforts include small molecules, monoclonal antibodies and biologics designed to clear plaques, inhibit tau aggregation or modulate neuroinflammation. Precision approaches harness biomarkers for early diagnosis, target engagement and patient stratification. Repurposing of existing drugs accelerates timelines by leveraging known safety profiles. Novel modalities such as gene therapies, enzyme treatments and combination regimens are under exploration. Success depends on optimised trial designs, adaptive protocols and incorporation of fluid and imaging biomarkers. Global collaboration and data sharing have become central to surmounting high attrition rates, with the goal of delivering safe, effective therapies that can delay onset or progression of AD.

Research from Nature Portfolio

A machine-learning framework applied transcriptional profiles from human neural cultures treated with 80 approved drugs to identify associations with AD pathology stages. By linking gene expression perturbations to Braak staging, this approach prioritised repurposing candidates with shared mechanisms. Top-scoring agents were examined for common target trends, providing a ranked list of drugs with potential efficacy. This method illustrates how computational analyses of existing compounds can nominate therapies for rapid validation in clinical settings.

Alzheimer's Disease Drug Development Strategies publication trend

The graph below shows the total number of articles in alzheimer's disease drug development strategies across all publications each year (not limited to Nature Index journals).

Technical terms

Amyloid-β: A peptide that aggregates into plaques, a hallmark of Alzheimer’s pathology.

Tau: A microtubule-associated protein that forms neurofibrillary tangles when abnormally phosphorylated.

Disease-modifying therapy: An intervention that alters the trajectory of the underlying disease process.

Biomarker: A measurable indicator of biological state or response, used for diagnosis, prognosis or treatment monitoring.

Repurposing: The strategy of testing existing drugs for new therapeutic indications based on mechanistic insights.

References

1. The “rights” of precision drug development for Alzheimer’s disease. Alzheimer's Research & Therapy (2019).
2. Machine learning identifies candidates for drug repurposing in Alzheimer’s disease. Nature Communications (2021).
3. New approaches to symptomatic treatments for Alzheimer’s disease. Molecular Neurodegeneration (2021).
4. The Alzheimer’s disease drug development landscape. Alzheimer's Research & Therapy (2021).
5. Repurposed agents in the Alzheimer’s disease drug development pipeline. Alzheimer's Research & Therapy (2020).